Topadur Pharma

News

8.9.22

TOPADUR has been selected as a TOP 100 Scale-up 2022 with unicorn potential

TOPADUR Pharma AG has been selected among Switzerland's most promising scale-ups in 2022. Huge thanks to everyone of our team, supporters, and partners believing in us along the way!

Please check out the link below.

‍

Download Document Dokument herunterladen https://www.top100startups.swiss/On-the-road-to-growth-Switzerlands-most-promising-scaleups-in-2022 https://www.top100startups.swiss/On-the-road-to-growth-Switzerlands-most-promising-scaleups-in-2022

10.11.20

Press Release

TOPADUR announces positive results from an interim analysis of Phase I trial

TOPADUR announces positive results from an interim analysis of Phase I clinical trial with their new wound healing drug candidate.

7.9.23

News

TOPADUR has been selected as a TOP 100 Scale-up 2023 with unicorn potential

We are proud to be recognized as one of Switzerland's most promising scale-ups in 2023.

9.11.22

News

Scientific Publication in Pharmaceutics

Topical Wound Treatment with a NO-Releasing PDE5 Inhibitor Formulation Enhances Blood Perfusion and Promotes Healing in Mice.

TOPADUR has been selected as a TOP 100 Scale-up 2022 with unicorn potential

TOPADUR announces positive results from an interim analysis of Phase I trial

TOPADUR has been selected as a TOP 100 Scale-up 2023 with unicorn potential

Scientific Publication in Pharmaceutics

About us

Approach

Disease Areas

Investors

Contact